JP2003523207A5 - - Google Patents

Download PDF

Info

Publication number
JP2003523207A5
JP2003523207A5 JP2001561030A JP2001561030A JP2003523207A5 JP 2003523207 A5 JP2003523207 A5 JP 2003523207A5 JP 2001561030 A JP2001561030 A JP 2001561030A JP 2001561030 A JP2001561030 A JP 2001561030A JP 2003523207 A5 JP2003523207 A5 JP 2003523207A5
Authority
JP
Japan
Prior art keywords
antibody
liv
polypeptide
binds
atcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001561030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/002622 external-priority patent/WO2001055178A2/en
Publication of JP2003523207A publication Critical patent/JP2003523207A/ja
Publication of JP2003523207A5 publication Critical patent/JP2003523207A5/ja
Withdrawn legal-status Critical Current

Links

JP2001561030A 2000-01-25 2001-01-25 Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用 Withdrawn JP2003523207A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17795100P 2000-01-25 2000-01-25
US60/177,951 2000-01-25
US19576100P 2000-04-10 2000-04-10
US60/195,761 2000-04-10
PCT/US2001/002622 WO2001055178A2 (en) 2000-01-25 2001-01-25 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2003523207A JP2003523207A (ja) 2003-08-05
JP2003523207A5 true JP2003523207A5 (https=) 2008-05-22

Family

ID=26873811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001561030A Withdrawn JP2003523207A (ja) 2000-01-25 2001-01-25 Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用

Country Status (10)

Country Link
US (3) US7285382B2 (https=)
EP (1) EP1263780A2 (https=)
JP (1) JP2003523207A (https=)
KR (1) KR20020073181A (https=)
AU (1) AU3458401A (https=)
CA (1) CA2395832A1 (https=)
IL (2) IL150592A0 (https=)
MX (1) MXPA02007190A (https=)
WO (1) WO2001055178A2 (https=)
ZA (1) ZA200205191B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU2003211947A1 (en) 2002-02-20 2003-09-09 Sysmex Corporation PRIMERS FOR NUCLEIC ACID AMPLIFICATION IN DETECTING HOUSEKEEPING GENE mRNA AND TEST METHOD USING THESE PRIMERS
JP2006520194A (ja) * 2003-01-27 2006-09-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｉｇｓｆ９およびｌｉｖ−１を使用して癌を処置するための組成物および方法
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
US7572443B2 (en) 2003-11-13 2009-08-11 California Pacific Medical Center Anti-PECAM therapy for metastasis suppression
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
JPWO2005063301A1 (ja) * 2003-12-26 2007-07-19 平野　俊夫 Ｅｍｔ誘導剤
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
US20080020474A1 (en) * 2004-03-30 2008-01-24 Riken Method of Analyzing Biosample by Laser Ablation and Apparatus Therefor
EP1833970A2 (en) * 2004-12-22 2007-09-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
CN101622273A (zh) * 2006-04-13 2010-01-06 诺瓦提斯疫苗和诊断公司 治疗、诊断或检测与liv-1过量表达相关的癌症的方法
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US8097423B2 (en) * 2007-07-30 2012-01-17 Institute Of Virology MN/CA IX and breast cancer therapy
US20100092894A1 (en) * 2008-10-14 2010-04-15 Weihong Liu Bottom Antireflective Coating Compositions
BR112012010153B1 (pt) 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
US20140322705A1 (en) * 2010-08-20 2014-10-30 Thomas Jefferson University Cancer diagnostic and cancer therapeutic
JP6105481B2 (ja) 2010-12-06 2017-03-29 シアトル ジェネティクス，インコーポレーテッド Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3116999B1 (en) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Methods and compositions for secretion of heterologous polypeptides
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
CA2132500A1 (en) 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
RU2188819C2 (ru) 1996-08-12 2002-09-10 Селджин Корпорейшн НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US5860935A (en) 1996-10-29 1999-01-19 Novid Inc. Game apparatus and method for monitoring psycho-physiological responses to questions
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1999006673A1 (en) 1997-07-30 1999-02-11 Eg & G Sealol, Inc. Improved brush seal and method of making same
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
DE19813839A1 (de) 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe
JP2002507404A (ja) 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US6762020B1 (en) * 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
AU3752700A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
US6649342B1 (en) 1999-03-15 2003-11-18 Eos Biotechnology, Inc. Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
CA2368376A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
US6780586B1 (en) 1999-11-29 2004-08-24 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
WO2002016939A2 (en) * 2000-08-18 2002-02-28 Eos Biotechnology, Inc. Methods of diagnosis of cancer and screening for cancer modulators
JP2005503760A (ja) * 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof

Similar Documents

Publication Publication Date Title
JP2003523207A5 (https=)
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
TWI432452B (zh) 針對ｈｅｒ-３之抗體類及其用途
JP5601836B2 (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
US8722362B2 (en) Monoclonal antibodies against HER2 antigens, and uses therefor
US20030086929A1 (en) Treatment of prostate cancer by inhibitors of ATP synthase
JPH04503012A (ja) Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５
JP2010537671A5 (https=)
CN115998901B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
MX2011004684A (es) Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
Keydar et al. Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens.
KR20080059449A (ko) 치료용 약제
US7399469B2 (en) Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
CA2605745A1 (en) Cancer specific pcna isoform binding antibodies and uses thereof
CA2355870A1 (en) Reagents and methods useful for detecting diseases of the breast
KR100473824B1 (ko) 상피종의진단및치료방법
CN119343378A (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
KR20100034720A (ko) 피에이유에프(ｐａｕｆ) 특이적인 인간 단일클론항체, 이를 포함하는 암 치료용 조성물, 이를 이용하는 암의 진단방법
JPWO2010098503A1 (ja) 間質性肺炎治療剤
WO2019045086A1 (ja) 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
NZ233147A (en) Retinoblastoma gene product antibodies and their use in assays for tumor cells
AU2014357450B2 (en) Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
CN113321730B (zh) Cldn18.2抗体及其应用
US7303914B2 (en) Monoclonal antibody against human hepatoma and use thereof
CN116410305A (zh) 一种用于检测宫颈癌病理组织中hpv16 e6蛋白的单克隆抗体